The second patent for peripheral artery disease-focused device company XableCath has been granted in the USA. The new patent specifically describes a catheter that controls tissue contact and has a rigid ring implement that opens a blood vessel occlusion by rotating the ring against the occlusion, thus clearing the vessel and providing access across the lesion.
“Our proprietary design enables the XableCath to easily slide past an occluding atheroma through the true lumen of the vessel,” stated the company’s president and CEO, Lisa Dunlea. “The granting of this second patent provides broad coverage and a strong foundation for XableCath’s intellectual property portfolio and future product development plans.”
Company board member Oded Ben-Joseph commented, “Following the recent FDA clearance for XableCath’s blunt tip catheter, this new patent provides an additional testimonial for the company’s innovative and unique design to enable a safe and rapid passage through chronic peripheral total occlusions, both above and below the knee. We believe that the ability to treat complex occlusions addresses a clear and unmet clinical need and will ultimately help both patients and physicians.”
The patented support catheter is designed to treat peripheral artery disease by facilitating over-the-wire passage through the true artery lumen enabling endovascular treatment options such as angioplasty, stenting, or atherectomy. The technology is designed to modify atheroma edges facilitating rapid and safe passage across tough arterial lesions in the peripheral vascular.
The company is on pace to perform its first cases in the USA during the first half of 2018.
